1, 5, and 7 |
MTT |
unreported |
[9] |
diphyllin (3) |
MTT |
unreported |
[10] |
justicidin A (5), diphyllin (3), and tuberculatin (4) |
MTT, ELISA kit |
tumor necrosis factor-α augment |
[11] |
cleistanone (1), 7 |
MTT |
unreported |
[12] |
2-6 |
MTT, flow cytometry, P388 leukemia model |
G0/G1 phase blockade |
[13] |
2-5 |
MTS |
unreported |
[14] |
1, 3, and 4 |
MTT, PI and EB staining, Western blot |
mitochondrial-mediated apoptosis induction, Bcl-2 decrease, Bax increase |
[15] |
5 and 6 |
MTT, kDNA decatenation assay, tubulin polymerization assay |
Topo II and tubulin inhibition |
[16] |
3 |
MTT, Western blot |
Topo II and HADC1 inhibition |
[17] |
5d |
MTT, Western blot |
mitochondrial-mediated apoptosis induction, Bcl-2 decrease, Bax increase |
[18] |
3a and 3e |
MTT, colorimetric assay |
vacuolar H+-ATPase inhibition |
[19] |
3a |
MTT, colorimetric assay |
vacuolar H+-ATPase inhibition |
[20] |
ZT-25 |
MTT, Western blot |
G1/G0 phase blockade, mitochondrial membrane potential dissipation, ATP depletion, Bcl-2 downregulation, Bax and cleaved caspase-3 upregulation. Autophagy induction, LC3 I to LC3 II, Beclin-1 increase, and p-mTOR decrease |
[22] |
1e |
MTT, lysosome acidity assay |
vacuolar H+-ATPase inhibition |
[23] |
1, 4, and 7 |
MTT, transwell invasion assay |
unreported |
[24] |
2I |
MTT, vacuolar H+-ATPase activity assay kit |
vacuolar H+-ATPase inhibition |
[25] |
diphyllin, 5c3, and 5c4 |
MTT, vacuolar H+-ATPase activity assay kit, molecular docking |
vacuolar H+-ATPase inhibition |
|
diphyllin |
MTT, vacuolar H+-ATPase activity assay kit, Western blot, real-time PCR |
Wnt/β-catenin signaling inhibition (phospho-LRP6 and β-catenin expression inhibition, c-Myc and cyclin D1 gene downregulation) |
[27] |
15 |
Sulforhodamine B (SRB), MTT, DNA fragmentation electrophoresis, flow cytometry |
topoisomerase II inhibition, G0/G phase arrest |
[28] |
arylnaphthalene lignan (HJC) |
MTT, Western blot, real-time PCR |
activation of caspase 3 cascade, SOD inhibition, ROS elevation |
[47] |
HJB, HJA, JB, and CME |
MTT, SOD activity assay kit, flow cytometry, Western blot |
SOD inhibition, ROS elevation, caspase-dependent intrinsic and/or extrinsic apoptosis pathways |
[29] |
1 and 7 |
MTT, Western blot, Topoisomerase II assay, hollow fiber assay |
caspase 3-dependent apoptosis |
[30] |
Cleistanthin-A and Cleistanthoside A tetraacetate |
MTT, vacuolar H+-ATPase activity assay kit |
vacuolar H+-ATPase inhibition |
[31] |
5 |
MTT |
unreported |
[32] |
Justicidin B |
MTT, Western blot |
Bax/Bcl-2 ratio augment and caspase-3/7 activation |
[33] |
Cleistanthin A |
MTT, Western blot, vacuolar H+-ATPase activity assay kit |
MMP-2 and MMP-9 inhibition, vacuolar H+-ATPase inhibition |
[34] |
diphyllin |
MTT, real-time PCR |
decreased the mRNA expressions of mTORC1, HIF-1α, and VEGF |
[35] |
7c |
MTT |
unreported |
[37] |
M3 |
MTT, Western blot, CytoDYNAMIX Screen 03 Tubulin Polymerization assay |
caspase 3-dependent apoptosis, promotion of microtubule depolymerization |
[36] |
TAARD |
MTT, Western blot |
TLR1/NF-κB and TLR3/STAT3 pathway inhibition |
[38] |
Cleistanthin A |
MTT, Western blot, real-time PCR |
β-catenin pathway inhibition |
[39] |
ECDD-S27 |
MTT, immunoblot analysis |
restrain of autophagic flux and inhibition of vacuolar H+-ATPase activity |
[40] |
diphyllin derivatives |
MTT, UF-LC/MS screening assay, molecular docking |
COX-2 inhibition |
[41] |
15 |
MTT, Western blot, flow cytometry, mouse pancreatic cancer model |
G0/G1 phase blockade, CDK4, and cyclin D1 decrease |
[42] |
PHY34 |
MTT, mass spectrometry-based chemoproteomics |
targeting ATP6V0A2 subunit to induce autophagy inhibition and interacting with CAS to alter the nuclear localization of proteins |
[44] |
3 |
MTT, transwell invasion and scratch wound assay, vacuolar H+-ATPase activity assay kit |
vacuolar H+-ATPase inhibition |
[45] |
diphyllin |
MTT, AO/EB dual staining assay, flow cytometry, wound-healing assay |
apoptosis induction |
[46] |